

ASX RELEASE

Shares to be released from ASX imposed escrow

Wellington, NZ, 13 April 2018: <u>Volpara Health Technologies</u> ("Volpara"; ASX: VHT), a digital health company focused on early detection of breast cancer by improving quality of screening using artificial intelligence (AI), advises that 51,482,213 ordinary shares are due to be released from compulsory ASX restriction on 30 April 2017.

Following the release of the shares Volpara has a total of 145,493,121 ordinary shares on issue, all of which will be quoted on ASX. Furthermore, these 51,482,213, which are held by the founders and directors have been voluntarily escrowed for a further 12-month period from that date as noted in the ASX release dated 15 March 2018. In addition, Volpara also has 12,083,162 unlisted options on issue.

An Appendix 3B seeking quotation of the 51,482,213 ordinary shares to be released from ASX restriction is attached.

ENDS.

About Volpara Health Technologies Limited (ASX: VHT)

Founded in 2009 from research originally conducted at Oxford University, VHT is based in Wellington, New Zealand, and facilitates the early detection of breast cancer through its digital health solutions to enable personalised, high-quality breast cancer screening based on objective measurements of breast density. The Company's intelligent, cloud-based *VolparaEnterprise*™ platform assists breast clinics to more efficiently manage their business and facilitates benchmarking and efficiencies through artificial intelligence.

VHT has a number of patents and trademarks and regulatory clearances, including FDA and CE, supporting its technology and services. An ASX-listed company that raised A\$20M through an IPO and subsequent share issue in 2016, VHT has customers and/or research projects in 36 countries.

www.volparasolutions.com

For further information, please contact:

Ralph Highnam, CEO Volpara Health Technologies ralph.highnam@volparasolutions.com t: +64 21 149 0541 Kyahn Williamson WE Buchan kwilliamson@buchanwe.com.au t: +61 3 9866 4722

Rule 2.7, 3.10.3, 3.10.4, 3.10.5

Appendix 3B

New issue announcement, application for quotation of additional securities and agreement

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 01/07/96 Origin: Appendix 5 Amended 01/07/98, 01/09/99, 01/07/00, 30/09/01, 11/03/02, 01/01/03, 24/10/05, 01/08/12, 04/03/13

N	ame	of	entity	
---	-----	----	--------	--

Name of Chilly		
Volpara Health Technologies Limited		
ABN		
NZCN: 2206998 ARBN: 609 946 867		

We (the entity) give ASX the following information.

Part 1 - All issues

You must complete the relevant sections (attach sheets if there is not enough space).

- 1 *Class of *securities issued or to **Ordinary Shares** be issued Number of *securities issued or 2 51,482,213 to be issued (if known) or maximum number which may be issued
- Principal terms of the 3 if options, +securities (e.g. exercise price and expiry date; if partly paid +securities, the amount outstanding and due dates for payment; if +convertible securities, the conversion price and dates for conversion)

Fully Paid Ordinary Shares released from 24 months ASX compulsory escrow now subject to 12-month voluntary escrow from the release date (i.e. until 30 April 2019)

⁺ See chapter 19 for defined terms.

4	Do the *securities rank equally in all respects from the *issue date with an existing *class of quoted *securities?	Yes
	If the additional *securities do not rank equally, please state: • the date from which they do • the extent to which they participate for the next dividend, (in the case of a trust, distribution) or interest payment • the extent to which they do	
	not rank equally, other than in relation to the next dividend, distribution or interest payment	
5	Issue price or consideration	N/A
	•	,
6	Purpose of the issue (If issued as consideration for the acquisition of assets, clearly identify those assets)	Ordinary Shares issued pursuant to the 24-month ASX compulsory escrow period having elapsed.
6a	Is the entity an *eligible entity that has obtained security holder approval under rule 7.1A?	N/A
	If Yes, complete sections 6b – 6h in relation to the *securities the subject of this Appendix 3B, and comply with section 6i	
6b	The date the security holder resolution under rule 7.1A was passed	N/A
6c	Number of *securities issued without security holder approval under rule 7.1	N/A

Appendix 3B Page 2 04/03/2013

⁺ See chapter 19 for defined terms.

6d	Number of *securities issued with security holder approval under rule 7.1A	N/A	
6e	Number of *securities issued with security holder approval under rule 7.3, or another specific security holder approval (specify date of meeting)	N/A	
6f	Number of *securities issued under an exception in rule 7.2	N/A	
6g	If *securities issued under rule 7.1A, was issue price at least 75% of 15 day VWAP as calculated under rule 7.1A.3? Include the *issue date and both values. Include the source of the VWAP calculation.	N/A	
6h	If *securities were issued under rule 7.1A for non-cash consideration, state date on which valuation of consideration was released to ASX Market Announcements	N/A	
6i	Calculate the entity's remaining issue capacity under rule 7.1 and rule 7.1A – complete Annexure 1 and release to ASX Market Announcements	36,343,280	
7	⁺ Issue dates	30 April 2018	
	Note: The issue date may be prescribed by ASX (refer to the definition of issue date in rule 19.12). For example, the issue date for a pro rata entitlement issue must comply with the applicable timetable in Appendix 7A.	3 1	
	Cross reference: item 33 of Appendix 3B.		
		Number	+Class
8	Number and +class of all +securities quoted on ASX (including the +securities in section 2 if applicable)	145,493,121*	Ordinary Shares* *Includes 51,482,213 Shares now under voluntary escrow, see Section 9

⁺ See chapter 19 for defined terms.

9 Number and *class of all *securities not quoted on ASX (including the *securities in section 2 if applicable)

Number	+Class
51,482,213	Fully Paid Ordinary
	Shares subject to 12-
	month voluntary
	escrow (i.e. 30 April
	2019)
12,083,162	Options over fully paid ordinary shares, exercisable at various prices by various dates

Dividend policy (in the case of a trust, distribution policy) on the increased capital (interests)

N/A			

Part 2 - Pro rata issue

11	Is security holder approval required?	N/A
	_	
12	Is the issue renounceable or non-renounceable?	
13	Ratio in which the *securities will be offered	
14	⁺ Class of ⁺ securities to which the offer relates	
15	⁺ Record date to determine entitlements	
16	Will holdings on different registers (or subregisters) be aggregated for calculating entitlements?	
17	Policy for deciding entitlements in relation to fractions	

Appendix 3B Page 4 04/03/2013

⁺ See chapter 19 for defined terms.

18	Names of countries in which the entity has security holders who will not be sent new offer documents
	Note: Security holders must be told how their entitlements are to be dealt with.
	Cross reference: rule 7.7.
19	Closing date for receipt of acceptances or renunciations
20	Names of any underwriters
21	Amount of any underwriting fee or commission
22	Names of any brokers to the
22	issue
23	Fee or commission payable to the broker to the issue
24	Amount of any handling fee payable to brokers who lodge acceptances or renunciations on behalf of security holders
	If the icous is continuent on
25	If the issue is contingent on security holders' approval, the date of the meeting
- (Data antidoment and accordance
26	Date entitlement and acceptance form and offer documents will be sent to persons entitled
27	If the entity has issued options, and the terms entitle option holders to participate on exercise, the date on which notices will be sent to option
	holders
28	Date rights trading will begin (if applicable)
3.0	Date rights trading will and (if
29	Date rights trading will end (if applicable)
30	How do security holders sell

⁺ See chapter 19 for defined terms.

Appendix 3B New issue announcement

	their entit	lements in full through	
31	of their e	ecurity holders sell <i>part</i> ntitlements through a nd accept for the	
32	of their e	ecurity holders dispose ntitlements (except by gh a broker)?	
33	⁺ Issue date	2	
	-		S oplying for quotation of securities
(a)	(tick one)	curities described in Part	1
(b)	Exam	byee incentive share securities who	nd of the escrowed period, partly paid securities that become fully paid en restriction ends, securities issued on expiry or conversion of convertible
Entiti	es that hav	ve ticked box 34(a)	
Addi	tional secu	ırities forming a new	v class of securities
Tick to docum	-	are providing the informat	ion or
35	add		securities, the names of the 20 largest holders of the he number and percentage of additional *securitie
36	+sec 1 - 1, 1,00 5,00 10,0	curities setting out the nu	r securities, a distribution schedule of the additiona umber of holders in the categories

Appendix 3B Page 6 04/03/2013

⁺ See chapter 19 for defined terms.

37	A copy of any trust deed for the additional *securities		
Entiti	es that have ticked box 34(b)		
38	Number of *securities for which *quotation is sought		
39	⁺ Class of ⁺ securities for which quotation is sought		
40	Do the *securities rank equally in all respects from the *issue date with an existing *class of quoted *securities?		
	If the additional *securities do not rank equally, please state: • the date from which they do • the extent to which they participate for the next dividend, (in the case of a trust, distribution) or interest payment • the extent to which they do not rank equally, other than in relation to the next dividend, distribution or interest payment		
41	Reason for request for quotation now Example: In the case of restricted securities, end of restriction period (if issued upon conversion of		
	another *security, clearly identify that other *security)		
42	Number and *class of all *securities quoted on ASX (<i>including</i> the *securities in clause 38)	Number	+Class

⁺ See chapter 19 for defined terms.

Quotation agreement

- [†]Quotation of our additional [†]securities is in ASX's absolute discretion. ASX may quote the [†]securities on any conditions it decides.
- 2 We warrant the following to ASX.
 - The issue of the *securities to be quoted complies with the law and is not for an illegal purpose.
 - There is no reason why those *securities should not be granted *quotation.
 - An offer of the *securities for sale within 12 months after their issue will not require disclosure under section 707(3) or section 1012C(6) of the Corporations Act.

Note: An entity may need to obtain appropriate warranties from subscribers for the securities in order to be able to give this warranty

- Section 724 or section 1016E of the Corporations Act does not apply to any applications received by us in relation to any *securities to be quoted and that no-one has any right to return any *securities to be quoted under sections 737, 738 or 1016F of the Corporations Act at the time that we request that the *securities be quoted.
- If we are a trust, we warrant that no person has the right to return the *securities to be quoted under section 1019B of the Corporations Act at the time that we request that the *securities be quoted.
- We will indemnify ASX to the fullest extent permitted by law in respect of any claim, action or expense arising from or connected with any breach of the warranties in this agreement.
- We give ASX the information and documents required by this form. If any information or document is not available now, we will give it to ASX before †quotation of the †securities begins. We acknowledge that ASX is relying on the information and documents. We warrant that they are (will be) true and complete.

Sign here:

Print name: Craig Hadfield

Company Secretary

Date:

13 April 2018

== == == ==

Appendix 3B Page 8 04/03/2013

⁺ See chapter 19 for defined terms.

Appendix 3B – Annexure 1

Calculation of placement capacity under rule 7.1 and rule 7.1A for eligible entities

Introduced 01/08/12 Amended 04/03/13

Part 1

Rule 7.1 – Issues exceeding 15% of capital			
Step 1: Calculate "A", the base figure from which the placement capacity is calculated			
Insert number of fully paid *ordinary securities on issue 12 months before the *issue date or date of agreement to issue	145,493,121		
Add the following:			
Number of fully paid ⁺ ordinary securities issued in that 12 month period under an exception in rule 7.2			
Number of fully paid ⁺ ordinary securities issued in that 12 month period with shareholder approval	Nil		
Number of partly paid ⁺ ordinary securities that became fully paid in that 12 month period			
Note: Include only ordinary securities here — other classes of equity securities cannot be added Include here (if applicable) the securities the subject of the Appendix 3B to which this form is annexed It may be useful to set out issues of securities on different dates as separate line items			
Subtract the number of fully paid ⁺ ordinary securities cancelled during that 12 month period	Nil		
"A"	145,493,121		

⁺ See chapter 19 for defined terms.

Step 2: Calculate 15% of "A"	
"B"	0.15
	[Note: this value cannot be changed]
Multiply "A" by 0.15	21,823,968
Step 3: Calculate "C", the amount of 7.1 that has already been used	of placement capacity under rule
Insert number of *equity securities issued or agreed to be issued in that 12 month period not counting those issued:	
 Under an exception in rule 7.2 	
Under rule 7.1A	
 With security holder approval under rule 7.1 or rule 7.4 	
 Note: This applies to equity securities, unless specifically excluded – not just ordinary securities Include here (if applicable) the securities the subject of the Appendix 3B to which this form is annexed It may be useful to set out issues of securities on different dates as separate line items 	
"C"	Nil
Step 4: Subtract "C" from ["A" x "l placement capacity under rule 7.1	3"] to calculate remaining
"A" x 0.15	
Note: number must be same as shown in Step 2	21,823,968
Subtract "C"	
Note: number must be same as shown in Step 3	Nil
Total ["A" x 0.15] – "C"	21,823,968
	[Note: this is the remaining placement capacity under rule 7.1]

Appendix 3B Page 10 04/03/2013

⁺ See chapter 19 for defined terms.

Part 2

Rule 7.1A – Additional placement capacity for eligible entities	
Step 1: Calculate "A", the base figure from which the placement capacity is calculated	
"A"	145,193,121
Note: number must be same as shown in Step 1 of Part 1	
Step 2: Calculate 10% of "A"	
"D"	0.10
	Note: this value cannot be changed
Multiply "A" by 0.10	14,519,312
Step 3: Calculate "E", the amount of placement capacity under rule 7.1A that has already been used	
 Insert number of *equity securities issued or agreed to be issued in that 12 month period under rule 7.1A Notes: This applies to equity securities – not just ordinary securities Include here – if applicable – the securities the subject of the Appendix 3B to which this form is annexed Do not include equity securities issued under rule 7.1 (they must be dealt with in Part 1), or for which specific security holder approval has been obtained It may be useful to set out issues of securities on different dates as separate line items 	
"E"	Nil

⁺ See chapter 19 for defined terms.

Step 4: Subtract "E" from ["A" x "D"] to calculate remaining placement capacity under rule 7.1A	
"A" x 0.10	14,519,312
Note: number must be same as shown in Step 2	
Subtract "E"	Nil
Note: number must be same as shown in Step 3	
Total ["A" x 0.10] – "E"	14,519,312
	Note: this is the remaining placement capacity under rule 7.1A

Appendix 3B Page 12 04/03/2013

⁺ See chapter 19 for defined terms.